The evaluation of adenoviral p53-mediated bystander effect in gene therapy of cancer

Cancer Gene Therapy

Volumn 6, Issue 4, 1999, Pages 291-301

  Rizk, Nabil P ^a   Chang, Michael Y ^a   El Kouri, Claude ^a   Seth, Prem ^b   Kaiser, Larry R ^a   Albelda, Steven M ^a   Amin, Kunjlata M ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Adenovirus; Bystander effect; Cancer; Gene therapy; p53

Indexed keywords

MESSENGER RNA; PROTEIN P53;

ADENOVIRUS; ANIMAL; APOPTOSIS; ARTICLE; CELL CULTURE; CELL DIVISION; EVALUATION; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; METABOLISM; MOUSE; NEOPLASM; PATHOLOGY; SURVIVAL; TUMOR SUPPRESSOR GENE;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; CELL DIVISION; EVALUATION STUDIES; GENE THERAPY; GENES, P53; GENETIC VECTORS; HUMANS; MICE; NEOPLASMS; RNA, MESSENGER; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033163107     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700059     Document Type: Review

References (39)

1. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323-331.
2. Harris MP, Sutjipto S, Wills KN, et al. Adenovirusmediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein. Cancer Gene Ther. 1996;32:121-130.
3. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst. 1996;88:1442-1455.
4. Nielsen LL, Maneval DC. p53 tumor suppressor gene therapy for cancer. Cancer Gene Ther. 1998;5:52-63.
5. Fujiwara T, Cai D, Georges RN, Mukhopadhyay T, Grimm EA, Roth JA. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst. 1994;86:1458-1462.
6. Nguyen DM, Wiehle SA, Koch PE, et al. Delivery of the p53 tumor suppressor gene into lung cancer cells by an adenovirus/DNA complex. Cancer Gene Ther. 1997;4:191-198.
7. Qazilbash MH, Xiao O, Seth P, Cowan KH, Walsh CE. Cancer gene therapy using a novel adeno-associated virus vector expressing human wild-type p53. Gene Ther. 1997; 4:675-682.
8. Xu M, Kumar D, Srinivas S, et al. Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity. Hum Gene Ther. 1997;8:177-185.
9. Nielson LL, Dell J, Maxwell E, Armstrong L, Maneval D, Catino JJ. Efficacy of p53 adenovirus-mediated gene therapy against human breast cancer xenografts. Cancer Gene Ther. 1994;4:129-138.
10. Clayman GL, El-Naggar AK, Roth JA, et al. In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res. 1995;55:1-6.
11. Kock H, Harris MP, Anderson SC, et al. Adenovirusmediated p53 gene transfer suppresses growth of human glioblastoma cells in vitro and in vivo, Int J Cancer. 1996;67:808-815.
12. Mujoo K, Maneval KC, Anderson SC, Gutterman JU. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene. 1996;12:1617-1623.
13. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang W, Owen-Schwab LB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res. 1994;54: 2287-2291.
14. Roth JA, Nguyen D, Lawrence DD, et al. Retrovirusmediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med. 1996;2:985-991.
15. Pope IM, Poston GJ, Kinsella AR. The role of the bystander effect in suicide gene therapy. Eur J Cancer. 1197;33:1005-1016.
16. Smythe WR, Hwang HC, Elshami AA, et al. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thorac Surg. 1994; 57:1395-1401.
17. Katayose D, Gudas J, Nguyen H, Srivastava S, Cowan K, Seth P. Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells. Clin Cancer Res. 1995;1:889-897.
18. Elshami AA, Saavedra A, Zhang H, et al. Gap junctions play a role in the "bystander effect" of the herpes simplex virus thymidine kinase/ganciclovir system in vitro. Gene Ther. 1996;3:85-92.
19. Nolan GP, Fieing S, Nicolas JF, Herzenberg LA. Fluorescence-activated cell analysis and sorting of viable mammalian cells based on β-D-galactosidase activity after transduction of Escherichia coli lacZ. Proc Natl Acad Sci USA. 1988;85:2603-2607.
20. Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol chloroform extraction method. Anal Biochem. 1987;162:156-159.
21. Masuda H, Miller C, Koffler HP, Cline MJ. Rearrangement of the p53 gene in human ostegenic sarcomas. Proc Natl Acad Sci USA. 1987;84:7716-7719.
22. Laemmli UK. Cleavage of structural proteins during the assembly of the head of a bacteriophage T4. Nature. 1970;227:680-685.
23. Ungar S, Van de Meeren A, Tammilehol L, Mattson K, Gerwin BL. High levels of MDM2 are not correlated with the presence of wild-type p53 in human malignant mesothelioma cell lines. Br J Cancer. 1996;74:1534-1540.
24. Cai D, Mukhopadhyay T, Liu Y, Fujiwara KT, Roth JA. Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. Hum Gene Ther. 1993;4:617-624.
25. Smythe WR, Hwang HC, Elshami AA, Amin KA, Albelda SM, Kaiser LR. Differential sensitivity of thoracic malignant tumors to adenovirus-mediated drug sensitization gene therapy. J Cardiovasc Surg. 1995;109:626-631.
26. Smythe WR, Hwang HC, Elshami AA, et al. Treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann Surg. 1995;222:78-86.
27. Rakkar ZL, Katayose Y, Kim M, et al. Efficacy of multiple administrations of a recombinant adenovirus expressing wild-type p53 in an immune-competent mouse tumor model. Gene Ther. 1998;5:605-613.
28. Munshi A, Ramesh R, Marrogi A, Freeman S. Evaluation of adenovirus p53-mediated bystander effect in vivo. Proc Am Assoc Cancer Res. 1997;38:343 (abstract).
29. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science. 1994;265:1582-1584.
30. Van-Meir EG, Polverini PJ, Chazin VR, Huang HJ, Tribolet N, Cavanee WK. Release of an inhibitor of angiogenesis upon induction of wild-type p53 expression in glioblastoma cells. Nat Genet. 1994;8:171-176.
31. Takahashi Y, Bucana CD, Cleary KR, Ellis LM.p53, vessel count, and vascular endothelial growth factor expression in human colon cancer. Int J Cancer. 1998;79:34-38.
32. Seth P, Brinkmann U, Schwartz GN, et al. Adenovirusmediated gene transfer to human breast tumor cells: an approach for cancer gene therapy and bone marrow purging. Cancer Res. 1996;56:1346-1351.
33. Hamada K, Alemany R, Zhang W, et al. Adenovirusmediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Res. 1996;56:3047-3054.
34. Asgari K, Sesterhenn IA, Mcleod DG, et al. Inhibition of the growth of pre-established subcutaneous tumor nodules of human prostate cancer cells by single injection of the recombinant adenovirus p53 expression vector. Int J Cancer. 1997;7:377-382.
35. Liu T, Zhang W, Taylor DL, Roth JA, Goepfert H, Clayman GL. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res. 1994;54: 3662-3667.
36. Yang C, Cirielli C, Capogrossi MC, Passaniti A. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res. 1995;55:4210-4213.
37. Zhang W, Fang X, Mazur W, French BA, Georges RN, Roth JA. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther. 1994;1:5-13.
38. Wills KN, Maneval DC, Menzel P, et al. Development and characterization of recombinant adenovirus encoding human p53 for gene therapy. Hum Gene Ther. 1994;5:1079-1088.
39. Boa J, Zhang W, Kou MT. Adenoviral delivery of recombinant DNA into transgenic mice bearing hepatocellular carcinomas. Hum Gene Ther. 1997;7:355-365.